等待开盘 04-01 09:30:00 美东时间
-0.004
-0.45%
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.72) per share. This is a 199.2 percent decrease over earnings of $3.75 per share from the same period last year.
03-31 04:34
FDA provided constructive feedback on Company's analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with
03-25 20:06
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label
03-10 04:13
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 96.61 percent increase over losses of $(11.52) per share from the
2025-11-14 21:40
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 205.0% to $27.05...
2025-11-14 01:06
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX®
2025-11-13 21:40
今日重点评级关注:富国银行:维持Kyverna Therapeutics"超配"评级,目标价从24美元升至27美元;Chardan Capital:维持Oculis Holding"买入"评级,目标价从33美元升至51美元
2025-10-09 10:51
Aegis Capital analyst David Bouchey reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $7.2 price target.
2025-10-09 00:43